Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery

Future Medicinal Chemistry

Volumn 7, Issue 17, 2015, Pages 2351-2369

  Bueters, Tjerk ^a   Gibson, Christopher ^a   G Visser, Sandra A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DRUG DEVELOPMENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; EFFECTIVE CONCENTRATION; HUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROBABILITY; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REVIEW; TRANSLATIONAL RESEARCH; ANIMAL; CHEMISTRY; DOSE RESPONSE; HALF LIFE TIME; IC50; METABOLISM;

DRUG;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; PHARMACEUTICAL PREPARATIONS;

EID: 84949449315     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.143     Document Type: Review

References (93)

1. Visser SA, Aurell M, Jones RD et al. Model-based drug discovery: implementation and impact. Drug Discov. Today 18, 764-775 (2013).
2. Schuck E, Bohnert T, Chakravarty A et al. Preclinical pharmacokinetic/pharmacodynamics modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape. AAPS J. 17, 462-473 (2015).
3. Bueters T, Ploeger BA, Visser SA. The virtue of translational PKPD modeling indrug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov. Today 18, 853-862 (2013).
4. Gabrielsson J, Fjellström O, Ulander J, Rowley M, Van Der Graaf PH. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr. Top. Med. Chem. 11, 404-418 (2011).
5. Milligan PA, Brown MJ, Marchant B et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
6. Allerheiligen SR. Impact of modeling and simulation: myth or fact Clin. Pharmacol. Ther. 96, 413-415 (2014).
7. Morgan P, Van Der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419-424 (2012).
8. Cook D, Brown D, Alexander R et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).
9. Grasela TH, Fiedler-Kelly J, Walawander CA et al. Challenges in the transition to model-based development. AAPS J. 7, E488-E495 (2005).
10. Bonate PL. What happened to the modeling and simulation revolution Clin. Pharmacol. Ther. 96, 416-417 (2014).
11. Ploeger BA, Van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab. Pharmacokinet. 24, 3-15 (2009).
12. Felmlee MA, Morris ME, Mager DE. Mechanism-based pharmacodynamic modeling. Methods Mol. Biol. 929, 583-600 (2012).
13. Sundqvist M, Lundahl A, Nagard MB, Bredberg U, Gennemark P. Quantifying and communicating uncertainty in preclinical human dose prediction. CPT Pharmacometrics Syst. Pharmacol. 4, 243-254 (2015).
14. Lathia CD, Amakye D, Dai W et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin. Pharmacol. Ther. 86, 32-43 (2009).
15. Wagner JA, Ball JR. Implications of the institute of medicine report: evaluation of biomarkers and surrogate endpoints in chronic disease. Clin. Pharmacol. Ther. 98(1), 12-15 (2015).
16. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22, 1432-1437 (2005).
17. Gobburu JV. Biomarkers in clinical drug development. Clin. Pharmacol. Ther. 86, 26-27 (2009).
18. Agoram BM, Van der Graaf PH. Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development. Bioanalysis 4, 1143-1145 (2012).
19. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst. Pharmacol. 1, e6 (2012).
20. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 2, e38 (2013).
21. Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29, 186-191 (2008).
22. Visser SA, de Alwis DP, Kerbusch T, Stone JA, Allerheiligen SR. Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst. Pharmacol. 3, e142 (2014).
23. Vicini P, Van der Graaf PH. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan Clin. Pharmacol. Ther. 93, 379-381 (2013).
24. Jones HM, K Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacomet. Syst. Pharmacol. 2, e63 (2013).
25. Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometrics Syst. Pharmacol. 3, e148 (2013).
26. Shepard T, Scott G, Nordmark A, Bouzom F. Physiology based models in regulatory submissions: output from the ABPI/MHRA forum on pysiologically based modeling and simulation. CPT Pharmacometrics Syst. Pharmacol. 4(4), 221-225 (2015).
27. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared with sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 25, 715-725 (2005).
28. Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin. Pharmacol. Ther. 90, 766-769 (2011).
29. Bueters TJ, Hoogstraate J, Visser SA. Correct assessment of new compounds using in vivo screening models can reduce false positives. Drug Discov. Today 14, 89-94 (2009).
30. Hunter AJ. Have animal models of disease helped or hindered the drug discovery process Ann. NY Acad. Sci. 1245, 1-2 (2011).
31. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114-118 (2014).
32. McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 87, 162-171 (2014).
33. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
34. Gryn SE, Hegele RA. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opin. Pharmacother. 16, 1255-1262 (2015).
35. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117, 3603-3609 (2007).
36. Zhang R, Kavana M. Quantitative analysis of receptor allosterism and its implication for drug discovery. Expert Opin. Drug Discov. 10(7), 763-780 (2015).
37. Van der Graaf PH, Van Schaick EA, Visser SA et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. 290, 702-709 (1999).
38. Bauer R.A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov. Today 20(9), 1061-1073. (2015).
39. Niva C, Parkinson J, Olsson F et al. Has inhibition of A production adequately been tested as therapeutic approach in mild AD A model-based meta-analysis of-secretase inhibitor data. Eur. J. Clin. Pharmacol. 69, 1247-1260 (2013).
40. Visser SA, Wolters FL, Gubbens-Stibbe JM et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J. Pharmacol. Exp. Ther. 304, 88-101 (2003).
41. Barbier AJ, Hilhorst M, Van Vliet A et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective 7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin. Ther. 37, 311-324 (2015).
42. Eddins D, Hamill TG, Puri V et al. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology (Berl.).
43. Umbricht D, Martin-Facklam M, Pizzagalli E et al. Glycine transporter type 1 (GLYT1) inhibition RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophr. Bull. 37, 324 (2011).
44. Wager TT, Kormos BL, Brady JT et al. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J. Med. Chem. 56, 9771-9779 (2013).
45. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Lea and Febiger, Malvern, PA, USA (2010).
46. Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis. 61, 55-71 (2014).
47. Nicholas T, Duvvuri S, Leurent C et al. Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Advance. Alzheimer's Dis. 2 83-98 (2013).
48. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov. 9, 929-939 (2010).
49. Cui H, Zhang AJ, Chen M, Liu JJ. ABC transporter inhibitors in reversing multidrug resistance to chemotherapy. Curr. Drug Targets (2015) (Epub ahead of print).
50. Anderson PL, Kiser JJ, Gardner EM et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J. Antimicrob. Chemother. 66, 240-250 (2011).
51. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5, 297-305 (2013).
52. Diao L, Meibohm B. Tools for predicting the PK/PD of therapeutic proteins. Expert Opin. Drug Metab. Toxicol. 4, 1-11 (2015).
53. Lutz JD, Fujioka Y, Isoherranen N. Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opin. Drug Metab. Toxicol. 6, 1095-1109 (2010).
54. Tummino PJ, Copeland RA. Residence time of receptorligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008).
55. Cusack KP, Wang Y, Hoemann MZ et al. Design strategies to address kinetics of drug binding and residence time. Bioorg. Med. Chem. Lett. 25, 2019-2027 (2015).
56. Zhang R. Which trails are your drugs taking Nat. Chem. Biol. 11(6), 382-383 (2015).
57. Dahl G, Akerud T. Pharmacokinetics and the drug-target residence time concept. Drug Discov. Today 18, 697-707 (2013).
58. Copeland RA. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin. Drug Discov. 5, 305-310 (2010).
59. Lu Y, Barton HA, Leung L et al. Cerebrospinal fluid-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodegener. Dis. 12, 36-50 (2013).
60. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M. Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm. Res. 24, 2031-2039 (2007).
61. Yamazaki S, Lam JL, Zou HY et al. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. Drug Metab. Dispos. 43, 54-62 (2015).
62. Eketjäll S, Janson J, Jeppsson F et al. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J. Neurosci. 33, 10075-10084 (2013).
63. Møller JB, Overgaard RV, Kjellsson MC et al. Longitudinal modeling of the relationship between mean plasma glucose and HbA1c following antidiabetic treatments. CPT Pharmacometrics Syst. Pharmacol. 2, e82 (2013).
64. Williams DS, McCracken PJ, Purcell M et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 56, 489-496 (2013).
65. Parkinson J, Visser SA, Jarvis P et al. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. J. Pharmacol. Toxicol. Methods. 68, 357-366 (2013).
66. Chien JY, Friedrich S, Heathman MA, De Alwis DP, Sinha V. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 7, E544-E559 (2005).
67. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758 (1999).
68. Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, Crizotinib. AAPS J. 15, 354-366 (2013).
69. Benson N, Matsuura T, Smirnov S et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3, 20120071 (2013).
70. Toni T, Dua P, Van der Graaf PH. Systems pharmacology of the NGF signaling through p75 and TrkA receptors. CPT Pharmacometrics Syst. Pharmacol. 3, e150 (2014).
71. Huntjens DR, Spalding DJ, Danhof M, Della Pasqua OE. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br. J. Pharmacol. 148, 396-404 (2006).
72. Maillard MP, Würzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol. Ther. 71, 68-76 (2002).
73. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect ofsynthetic opioids in the rat: correlation with the interaction at the muopioidreceptor. J. Pharmacol. Exp. Ther. 284, 1095-1103 (1998).
74. Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Curr. Opin. Pharmacol. 8, 549-556 (2008).
75. Higgins B, Glenn K, Walz A et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin. Cancer Res. 20, 3742-3752 (2014).
76. Zhang XY, Birtwistle MR, Gallo JM. A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway. CPT Pharmacometrics Syst. Pharmacol. 3, e92 (2014).
77. Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev. Clin. Pharmacol. 7, 711-730 (2014).
78. Brynne L, Bresell A, Sjögren N. Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine. J. Transl. Med. 11, 250 (2013).
79. Jansson-Lofmark R, Goransson F, Gabrielsson J. Quantitative comparisons between clinical efficacious concentrations and in vitro potency-what is the relation Presented at: 7th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology. Noordwijkerhout, The Netherlands, 23-25 April (2014).
80. Viberg A, Martino G, Lessard E, Laird JM. Evaluation of an innovative population pharmacokinetic-based design for behavioral pharmacodynamic endpoints. AAPS J. 14, 657-663 (2012).
81. Sjögren E, Svanberg P, Kanebratt KP. Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation. Drug Metab. Dispos. 40, 2273-2279 (2012).
82. Jones RD, Jones HM, Rowland M et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J. Pharm. Sci. 100, 4074-4089 (2011).
83. Ring BJ, Chien JY, Adkison KK et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J. Pharm. Sci. 100, 4090-4110 (2011).
84. Vuppugalla R, Marathe P, He H et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J. Pharm. Sci. 100, 4111-4126 (2011).
85. Poulin P, Jones RD, Jones HM et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci. 100, 4127-4157 (2011).
86. Yang J, Jamei M, Yeo KR, Tucker GT Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8, 676-684 (2007).
87. Brouwer KL, Keppler D, Hoffmaster KA et al. In vitro methods to support transporter evaluation in drug discovery and development. Clin. Pharmacol. Ther. 94, 95-112 (2013).
88. Zamek-Gliszczynski MJ, Lee CA, Poirier A et al. International Transporter Consortium. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther. 94, 64-79 (2013).
89. Lombardo F, Obach RS, Dicapua FM et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J. Med. Chem. 49, 2262-2267 (2006).
90. Smith DA, Beaumont K, Maurer TS, Di L. Volume of distribution in drug design. J. Med. Chem. 58(15), 5691-5698 (2015).
91. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2, 419-427 (2006).
92. Boulton DW, Kasichayanula S, Keung CF et al. Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br. J. Clin. Pharmacol. 75, 763-768 (2013).
93. Jonker DM, Kenna LA, Leishman D et al. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin. Pharmacol. Ther. 77, 572-582 (2005).